Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes

Lipids in Health and Disease

Yoshiya Tanaka¹  Nobuo Inokuchi²  Hirofumi Matsuoka³  Tadashi Arao¹  Sunao Yamamoto¹  Manabu Narisawa¹  Akira Kurozumi¹  Kenichi Tanaka¹  Maiko Hajime¹  Hiroko Mori¹  Yosuke Okada¹  Keiichi Torimoto¹ 

[1] First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushyu-shi 807-8555, Japan;Inokuchi Clinic, Fukuoka, Japan;Matsuoka Clinic, Fukuoka, Japan

关键词: Type 2 diabetes mellitus;    Hypercholesterolemia;    Ezetimibe;    Rosuvastatin;   

Others  :  833126
DOI  :  10.1186/1476-511X-12-137

 received in 2013-07-30, accepted in 2013-09-18,  发布年份 2013

【 摘 要 】

Background

Statins are used to treat hypercholesterolemia in patients with type 2 diabetes mellitus, but many of these patients fail to achieve the target LDL-C level. Recent reports have suggested that a synergistic effect can be obtained by concomitant administration of the cholesterol absorption inhibitor ezetimibe and a statin. However, in patients with type 2 diabetes who are already being treated with satins, it remains unclear whether it is more effective to add ezetimibe or to increase the statin dose. Therefore, this study was performed to examine the effects of these two regimens on LDL-C and lipoproteins.

Methods

The subjects were type 2 diabetic patients under treatment with rosuvastatin (2.5 mg daily), who had LDL-C levels ≥80 mg/dL. They were randomly allocated to a group that received add-on therapy with ezetimibe at 10 mg/day (combination group, n = 40) or an increase of the rosuvastatin dose to 5 mg/day (dose escalation group, n = 39). These two groups were compared at baseline and after 12 weeks of treatment.

Results

The percent change of LDL-C was −31% in the combination group and −12% in the dose escalation group. Both groups showed a significant decrease, but the decrease was greater in the combination group. In both groups, there was a significant decrease in the levels of small dense LDL-C, oxidized LDL and remnant-like lipoprotein cholesterol. For all of these parameters, the percent changes were greater in the combination group. Only the combination group showed a significant decrease of triglycerides. Multivariate analysis was performed to identify factors associated with reaching an LDL-C level <80 mg/dL. As a result, add-on therapy with ezetimibe was extracted as a factor related to improvement of LDL-C.

Conclusions

Compared with increasing the dose of rosuvastatin, the combination of rosuvastatin and ezetimibe not only achieves quantitative but also qualitative improvement of serum lipid levels in type 2 diabetic patients, suggesting that this combination could suppress the progression of atherosclerosis.

Trial registration

UMIN000011005

【 授权许可】

   
2013 Torimoto et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Sarwar N, Gao P, Emerging Risk Factors Collaboration, et al.: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
• [2]Sone H, Tanaka S, Tanaka S, et al.: Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan diabetes complications study (JDCS). J Clin Endocrinol Metab 2011, 96:3448-3456.
• [3]Tenenbaum A, Fisman EZ, Motro M, Adler Y: Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006, 5:20.
• [4]Teramoto T, Kashiwagi A, Mabuchi H: Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan atherosclerosis society guideline for diagnosis and treatment of hyperlipidemia in Japanese adults: a study of the Japan lipid assessment program (J-LAP). Curr Ther Res Clin Exp 2005, 66:80-95.
• [5]Altmann SW, Davis HR Jr, Zhu LJ, et al.: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
• [6]Morrone D, Weintraub WS, Toth PP, et al.: Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261.
• [7]Baigent C, Landray MJ, Reith C, SHARP Investigators, et al.: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
• [8]Arai H, Hiro T, Kimura T, et al.: More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome–sub-analysis of JAPAN-ACS study. J Atheroscler Thromb 2010, 17:1096-1107.
• [9]Takayama T, Hiro T, Yamagishi M, et al.: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009, 73:2110-2117.
• [10]Nohara R, Daida H, Hata M, Justification for Atherosclerosis Regression Treatment (JART) Investigators, et al.: Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: justification for atherosclerosis regression treatment (JART) study. Circ J 2012, 76:221-229.
• [11]Imano H, Noda H, Kitamura A, et al.: Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the circulatory risk in communities study (CIRCS). Prev Med 2011, 52:381-386.
• [12]Ito Y, Fujimura M, Ohta M, Hirano T: Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem 2011, 57:57-65.
• [13]Seino Y, Nanjo K, Tajima N, et al.: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010, 1:2-20.
• [14]Bays HE, Davidson MH, Massaad R, et al.: Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol 2011, 108:523-530.
• [15]Gylling H: Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int J Pract 2004, 58:859-866.
• [16]Barrios V, Amabile N, Paganelli F, et al.: Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005, 59:1377-1386.
• [17]Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM: Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol 2010, 9:20.
• [18]Ravid Z, Bendayan M, Delvin E, et al.: Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol 2008, 295:G873-G885.
• [19]Lally SE, Owens D, Tomkin GH: Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Diabetologia 2007, 50:217-219.
• [20]Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
• [21]Feingold KR, Grunfeld C, Pang M, et al.: LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992, 12:1496-1502.
• [22]Winkler K, Jacob S, Müller-Schewe T, et al.: Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 2012, 220:189-193.
• [23]Holvoet P, Vanhaecke J, Janssens S, et al.: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98:1487-1494.
• [24]Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
• [25]Itabe H, Ueda M: Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 2007, 14:1-11.
• [26]Uemura Y, Watarai M, Ishii H, et al.: Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012, 59:50-56.
• [27]Fujioka Y, Ishikawa Y: Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009, 16:145-154.
• [28]Watanabe N, Taniguchi T, Taketoh H, et al.: Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care 1999, 22:152-156.
• [29]Kasama T, Yoshino G, Iwatani I, et al.: Increased cholesterol concentration in intermediate density lipoprotein fraction of normolipidemic non-insulin-dependent diabetics. Atherosclerosis 1987, 63:263-266.
• [30]Nakamura T, Hirano M, Kitta Y, et al.: A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol 2012, 60:12-17.
• [31]Masuda D, Nakagawa-Toyama Y, Nakatani K, et al.: Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009, 39:689-698.
• [32]Labonté ED, Camarota LM, Rojas JC, et al.: Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1−/− mice. Am J Physiol Gastrointest Liver Physiol 2008, 295:776-783.
• [33]Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al.: Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb 2010, 17:914-924.
• [34]Galeano NF, Milne R, Marcel YL, et al.: Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 1994, 269:511-519.
• [35]Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR: Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res 2006, 47:2575-2580.
• [36]Deushi M, Nomura M, Kawakami A, et al.: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007, 581:5664-5670.
• [37]Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I: Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 2013, 100:46-52.
• [38]Muraoka T, Aoki K, Iwasaki T, et al.: Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2011, 60:617-628.